| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 04/10/2003 | US20030069428 Pharmaceutically active isoindoline derivatives |
| 04/10/2003 | US20030069406 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of blood disorders |
| 04/10/2003 | US20030069287 Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors |
| 04/10/2003 | US20030069249 Analgesics; central nervous system disorders |
| 04/10/2003 | US20030069248 Antiinflammatory agents; controlling cell cycle |
| 04/10/2003 | US20030069243 Novel substituted imidazole compounds |
| 04/10/2003 | US20030069241 Analgesics; central nervous system disorders; gastrointestinal disorder; therapy for drug abruse ; antiinflammatory agents |
| 04/10/2003 | US20030069228 Capase inhibitors; antiinflammatory agents |
| 04/10/2003 | US20030069221 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 04/10/2003 | US20030069201 Methods of using BCL-2 for the therapeutic treatment and prevention of diseases |
| 04/10/2003 | US20030069186 Chimeric natriuretic peptides |
| 04/10/2003 | US20030069181 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 04/10/2003 | US20030068785 Modified factor VIII |
| 04/10/2003 | US20030068333 Cocktail of >/= 4 different plasmid DNAs encoding corresponding respiratory syncytial virus antigens, coacervated with chitosan to formulate nanospheres |
| 04/10/2003 | US20030066753 Stable taurolidine electrolyte solutions |
| 04/10/2003 | CA2466020A1 Rsv gene expression vaccine |
| 04/10/2003 | CA2462795A1 Secreted proteins |
| 04/10/2003 | CA2462647A1 6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | CA2462601A1 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | CA2462599A1 Storage-stable fibrinogen solutions |
| 04/10/2003 | CA2462596A1 Storage-stable human fibrinogen solutions |
| 04/10/2003 | CA2462305A1 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | CA2462112A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 04/10/2003 | CA2461560A1 Inhibition of neonatal hyperbilirubinemia in breast fed infants |
| 04/10/2003 | CA2460917A1 Human tissue factor antibodies |
| 04/10/2003 | CA2455389A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 04/10/2003 | CA2455225A1 Novel proteins and nucleic acids encoding same |
| 04/09/2003 | EP1300424A1 Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
| 04/09/2003 | EP1300419A1 Antibody of human origin for inhibiting thrombocyte aggregation |
| 04/09/2003 | EP1300411A1 Novel disaccharides with anti-arthritic action |
| 04/09/2003 | EP1300166A1 Means for treatment of coronary artery obstructions |
| 04/09/2003 | EP1300148A2 Use of bismuth subgallate in inhibition of production of nitric oxide synthase |
| 04/09/2003 | EP1299548A1 Novel therapeutic molecular variants and uses thereof |
| 04/09/2003 | EP1299545A2 Drug metabolizing enzymes |
| 04/09/2003 | EP1299538A2 Secreted proteins |
| 04/09/2003 | EP1299522A2 Alteration of cell membrane |
| 04/09/2003 | EP1299424A1 COLD WATER SOLUBLE $g(b)-GLUCAN PRODUCT AND PROCESS FOR PREPARING THE SAME |
| 04/09/2003 | EP1299412A2 Protein modification and maintenance molecules |
| 04/09/2003 | EP1299410A2 GFR alpha1-RET SPECIFIC AGONISTS AND METHODS THEREFOR |
| 04/09/2003 | EP1299385A2 Fused cyclic modulators of nuclear hormone receptor function |
| 04/09/2003 | EP1299378A1 Tetrahydropyridino or piperidino heterocyclic derivatives |
| 04/09/2003 | EP1299374A1 Novel non-psychotropic cannabinoids |
| 04/09/2003 | EP1299358A2 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| 04/09/2003 | EP1299354A2 Factor viia inhibitory (thio)urea derivatives, their preparation and their use |
| 04/09/2003 | EP1299352A2 Compounds to treat alzheimer's disease |
| 04/09/2003 | EP1299351A1 Novel aryl, alkenyl, and alkynl 4-dedimethylaminotetracycline derivatives |
| 04/09/2003 | EP1299349A2 Compounds to treat alzheimer's disease |
| 04/09/2003 | EP1299125A1 Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| 04/09/2003 | EP1299032A1 DNA encoding human serine protease D-G |
| 04/09/2003 | EP1140243B1 Stent grafts with bioactive coatings |
| 04/09/2003 | EP0986580B1 Oligosaccharide mixtures having antithrombotic activity |
| 04/09/2003 | EP0946528B1 OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS |
| 04/09/2003 | EP0675956B1 New protein from urine named component b |
| 04/09/2003 | EP0674623B1 Bicyclic fibrinogen antagonists |
| 04/09/2003 | CN1409639A TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder |
| 04/09/2003 | CN1408858A Vermis kinase and its use in therapy of thrombus diseases |
| 04/09/2003 | CN1408857A Method for producing cumic(natto) kinase and cumic (natto) kinase thrombolytic medicine |
| 04/09/2003 | CN1408854A Preparation and application of recombined human betaine homocysteine methyl transferase |
| 04/09/2003 | CN1408438A Gene vaccine based on macrophage colony stimulating factor recepter and its use |
| 04/09/2003 | CN1408372A Method for using silkworm to express human interleukin 11 to produce medicine |
| 04/09/2003 | CN1105114C Sulfonyl divalent aryl alpha-hydroxy-iso-hydroximic acid compounds |
| 04/08/2003 | US6545055 Amidino-phenyl or -naphthyl aromatic amide derivatives |
| 04/08/2003 | US6545054 Alkenyl and alkynyl compounds as inhibitors of factor Xa |
| 04/08/2003 | US6545050 Aryl sulphonamide amino acid esters and analogues |
| 04/08/2003 | US6545037 Thromboxane A2 (TXA2) receptor and 5HT2 serotonergic receptor antagonists; 3-(6-(((4-chlorophenyl)sulphonyl)amino)-3-((2-(4-methyl-1 -piperazinyl)phenoxy)methyl)-5,6, 7,8-tetrahydro-1-naphthyl)propanoic acid for example |
| 04/08/2003 | US6544991 Compositions and methods for treating bacterial infections |
| 04/08/2003 | US6544982 3-aryl-5-aminoisoxazole derivatives |
| 04/08/2003 | US6544981 Anticoagulants, cardiovascular disorders |
| 04/08/2003 | US6544975 Mimetics that inhibit lipid peroxidation; for use in the treatment of diseases or disorders mediated by oxidative stress, such as asthma, inflammatory bowel disease, arthritis and vasculitis. |
| 04/08/2003 | US6544963 Alkali metal or alkali earth metal salt of carboxylmethyl cellulose, and a carrier; promoting cellular adhesion, wound healing, controlling bleeding |
| 04/08/2003 | US6544951 Antiinflammatory agents; autoimmune diseases, nervous system degradation |
| 04/08/2003 | US6544771 Retroviral gene therapy vectors and therapeutic methods based thereon |
| 04/08/2003 | US6544759 Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine |
| 04/08/2003 | US6544750 Prevent thrombosis |
| 04/08/2003 | US6544545 Providing needle-less device comprising a barrel member and a plunger, contacting first end of the barrel member to the patient's skin; depressing the plunger, thereby forcing medicament through the skin, to thereby administer medicament |
| 04/08/2003 | US6544544 Compound which disrupts microtubule function and polymeric carrier, with proviso that polymeric carrier is not a capsule |
| 04/08/2003 | CA2123548C Piperazine derivatives |
| 04/08/2003 | CA2050300C Tnf-inhibiting proteins and the preparation thereof |
| 04/04/2003 | WO2002030940A2 Low molecular serine protease inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals |
| 04/04/2003 | CA2424926A1 Low molecular serine protease inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals |
| 04/03/2003 | WO2003027637A2 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior |
| 04/03/2003 | WO2003027282A1 Adamts-15, -16, -17, -18 and -19 |
| 04/03/2003 | WO2003027263A2 Proteins associated with cell growth, differentiation, and death |
| 04/03/2003 | WO2003027245A2 CONVERSION OF RED BLOOD CELLS A, B, AND AB USING a-N-ACETYLGALACTOSAMINIDASES AND a-GALACTOSIDASE |
| 04/03/2003 | WO2003027234A2 Small organic molecule regulators of cell proliferation |
| 04/03/2003 | WO2003027147A2 Human coagulation factor vii polypeptides |
| 04/03/2003 | WO2003027128A1 Chemical compounds |
| 04/03/2003 | WO2003027111A1 Chemical compounds |
| 04/03/2003 | WO2003027102A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| 04/03/2003 | WO2003027075A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
| 04/03/2003 | WO2003026652A1 Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| 04/03/2003 | WO2003026636A1 Thrombus/thrombogenesis inhibitors |
| 04/03/2003 | WO2003026579A2 Combination therapies for immune mediated diseases |
| 04/03/2003 | WO2003026568A2 Androstanes as androgen receptor modulators |
| 04/03/2003 | WO2002100332A3 Isoxazoline compounds having mif antagonist activity |
| 04/03/2003 | WO2002092016A3 Therapeutic use of rank antagonists |
| 04/03/2003 | WO2002086078A3 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents |
| 04/03/2003 | WO2002078612A3 Thrombopoietin (tpo) synthebody for stimulation of platelet production |
| 04/03/2003 | WO2002070559A3 Nuclear hormone receptor ligand binding domains |
| 04/03/2003 | WO2002049694A3 Sterile bicarbonate-free dialysis concentrate solutions |